Evaluating the therapeutic potential of tofacitinib in Sjögren's disease: a comprehensive clinical and immunological assessment.

IF 4.7 2区医学 Q1 RHEUMATOLOGY

Rheumatology Pub Date : 2025-03-26 DOI:10.1093/rheumatology/keaf173

Qinghong Liu, Yuqing Zeng, Xiaoyan Xing, Bo Huang, Ruiling Feng, Yifan Wang, Naidi Wang, Xia Zhang, Yuhui Li, Linchong Su, Alexander Jacob, Julian L Ambrus, Long Shen, Lakshmanan Suresh, Di Yu, Xiang Lin, Jing He

{"title":"Evaluating the therapeutic potential of tofacitinib in Sjögren's disease: a comprehensive clinical and immunological assessment.","authors":"Qinghong Liu, Yuqing Zeng, Xiaoyan Xing, Bo Huang, Ruiling Feng, Yifan Wang, Naidi Wang, Xia Zhang, Yuhui Li, Linchong Su, Alexander Jacob, Julian L Ambrus, Long Shen, Lakshmanan Suresh, Di Yu, Xiang Lin, Jing He","doi":"10.1093/rheumatology/keaf173","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy, safety, and immunological effects of tofacitinib in patients with Sjögren's Disease (SjD), focusing on its impact on disease activity and immune cell modulation.Methods: Two independent cohort studies, one retrospective (Cohort I) and one prospective (Cohort II), were conducted to investigate the efficacy of oral tofacitinib treatment in patients diagnosed with SjD. All participants were evaluated for changes in disease activity and lab parameters. Circulating T cells were analyzed, focusing on follicular helper T (Tfh) cells and peripheral helper T (Tph) cells.Results: In cohort ǀ, 112 patients treated with tofacitinib showed a significant improvement in the ESSDAI score (median [IQR], 8.00 (4.25, 15.75) vs 6.50 (2.25, 12.75), p < 0.001). In cohort ‖, ten patients completed the 12-month treatment period. There was a significant reduction in ESSDAI scores at the 6th month compared with baseline (p = 0.001). 80% (8/10) of patients achieved a decrease of at least one point or 15% in ESSPRI scores. A significant reduction in the proportion of Th17 cells was observed (mean ± SD, 14.84 ± 7.70 vs 7.74 ± 4.24, p = 0.008). A decrease in Tfh and Tph cells was also observed, along with decreased pSTAT-3 levels in CD4+ T cells and disease activity scores. No serious adverse events were observed in the two cohorts.Conclusions: Tofacitinib effectively improves disease activity and immune regulation in SjD, and it is associated with suppressing Tfh and Tph cells, suggesting its potential as a treatment option.Trial registration: ClinicalTrials.gov Identifier: NCT05087589.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keaf173","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the efficacy, safety, and immunological effects of tofacitinib in patients with Sjögren's Disease (SjD), focusing on its impact on disease activity and immune cell modulation.

Methods: Two independent cohort studies, one retrospective (Cohort I) and one prospective (Cohort II), were conducted to investigate the efficacy of oral tofacitinib treatment in patients diagnosed with SjD. All participants were evaluated for changes in disease activity and lab parameters. Circulating T cells were analyzed, focusing on follicular helper T (Tfh) cells and peripheral helper T (Tph) cells.

Results: In cohort ǀ, 112 patients treated with tofacitinib showed a significant improvement in the ESSDAI score (median [IQR], 8.00 (4.25, 15.75) vs 6.50 (2.25, 12.75), p < 0.001). In cohort ‖, ten patients completed the 12-month treatment period. There was a significant reduction in ESSDAI scores at the 6th month compared with baseline (p = 0.001). 80% (8/10) of patients achieved a decrease of at least one point or 15% in ESSPRI scores. A significant reduction in the proportion of Th17 cells was observed (mean ± SD, 14.84 ± 7.70 vs 7.74 ± 4.24, p = 0.008). A decrease in Tfh and Tph cells was also observed, along with decreased pSTAT-3 levels in CD4+ T cells and disease activity scores. No serious adverse events were observed in the two cohorts.

Conclusions: Tofacitinib effectively improves disease activity and immune regulation in SjD, and it is associated with suppressing Tfh and Tph cells, suggesting its potential as a treatment option.

Trial registration: ClinicalTrials.gov Identifier: NCT05087589.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Rheumatology 医学-风湿病学

CiteScore

9.40

自引率

7.30%

发文量

1091

审稿时长

2 months

期刊介绍： Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press. Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.